SUN PHARMACEUTICAL INDUSTRIES LIMITED

2024 saw significant advancements in ophthalmology, including FDA approvals, AI and VR in healthcare, sustainable surgical practices, and new treatments for dry eye and retinal diseases. Clinical trials and patient understanding of conditions like dry eye disease also progressed.

FDA approved various treatments including Berdazimer Gel for Molluscum Contagiosum, Dupilumab for Atopic Dermatitis, Lifileucel for Melanoma, and others for conditions like Psoriasis, Rosacea, and Alopecia. Studies highlighted advancements in dermatology treatments and safety concerns over benzene in acne products.

2024 saw FDA approvals for treatments targeting conditions like atopic dermatitis, psoriasis, and prurigo nodularis. Notable approvals included Biofrontera's RhodoLED XL lamp, Arcutis Biotherapeutics' roflumilast cream, Sun Pharma's deuruxolitinib, Citius Pharmaceuticals' denileukindiftitox, Galderma's nemolizumab, Eli Lilly's lebrikizumab, UCB's bimekizumab, and Journey Medical's minocycline hydrochloride, enhancing therapeutic options across various dermatological conditions.

Ophthalmology Times reflects on 2024's key topics: AI in healthcare, VR for medical collaboration, operating room efficiency, sustainability in surgeries, and advancements in treatments like biosimilars and dry eye therapies. FDA approvals and clinical trials highlight ongoing progress in ophthalmology.

The Indian pharmaceutical industry is poised for significant growth by 2030, driven by AI, machine learning, and precision medicine. With a focus on innovation, quality, and global access, India aims to become a global hub for affordable, high-quality pharmaceuticals.

The Indian pharmaceutical industry is poised for significant growth, aiming to reach USD 130 billion by 2030, driven by innovation, AI, and precision medicine. Focus on research, global access, and quality improvement will position India as a global hub for affordable, high-quality pharmaceuticals.

Indian pharma companies are increasingly focusing on innovative R&D, establishing dedicated research firms in Western countries. This strategy de-risks main businesses and attracts investment, with promising drug pipelines indicating future growth and global expansion in innovative drugs.

Stuart Therapeutics appoints Tracy Valorie and Jason Werner to its Board of Directors, expanding to five members. They replace Robert O. Baratta and Diane Black, enhancing ophthalmology therapeutics expertise.